Karespot

All medications offered through Karespot are sourced from licensed, registered distributors of genuine pharmaceutical products, so you can be confident in their authenticity and quality.

For Tirzepatide (brand name: Mounjaro), the product is manufactured and marketed in India by Eli Lilly India Private Limited.

For Semaglutide-based medications, Karespot works with products manufactured by either Eris Lifesciences or Sun Pharmaceuticals Ltd, both of which are established, India-registered pharmaceutical companies.

For Semaglutide (brand name: Wegovy), the product is marketed in India by Novo Nordisk India Private Limited.

The Karespot Programme is a curated, doctor-guided journey designed to help patients manage side effects proactively, so they can stay consistent for longer. Alongside treatment, a dedicated health coach checks in regularly to support meal planning and daily habits. We emphasise a high-protein, nutrient-dense diet and provide sleep coaching to help improve energy, recovery, and long-term results.

Karespot helps you lose fat while staying strong. If you focus only on weight loss, you can end up losing muscle too, which slows your metabolism and makes maintenance harder. With GLP-1 support, we pair a high-protein eating approach with strength training so your results look better, feel better, and last longer.

Read more: the best macro ratio for weight loss on GLP-1.

Yes. PMOS (polyendocrine metabolic ovarian syndrome) is the new name for PCOS. The condition itself has not changed — only what we call it.

The change was made in May 2026 by a global consensus published in The Lancet. The old name was inaccurate: the condition does not involve true ovarian cysts, and calling it "polycystic" made it sound purely gynaecological when it is really a hormonal and metabolic condition. Your diagnosis, tests and treatment stay exactly the same.

Try our free PMOS (PCOS) symptom checker.

Because PMOS is driven largely by insulin resistance, which actively works against weight loss.

When your cells respond poorly to insulin, your body makes more of it. High insulin promotes fat storage, increases hunger, and pushes the ovaries to produce more androgens — which worsens insulin resistance again. It becomes a loop, which is why the diet and exercise that works for a friend may do very little for you.

It is not a lack of willpower. It is a metabolic headwind, and it usually needs to be addressed metabolically.

They can help with the weight and insulin resistance that drive PMOS — but it is important to be precise. In India these medicines are approved for weight management in obesity and for type 2 diabetes, not specifically for PMOS.

Because they improve insulin sensitivity and produce substantial weight loss, many women with PMOS and obesity find their cycles, androgen levels and metabolic markers improve as a result. Losing even 5–10% of body weight can restore ovulation for many women.

Whether this is right for you depends on your BMI, other conditions, and whether you are trying to conceive. That is a decision for a doctor.

Indian guidance uses lower BMI cut-offs than Western guidelines, because South Asians carry more visceral fat and develop metabolic disease at a lower weight.

The 2025 ESI obesity guidelines for India suggest anti-obesity medication, including GLP-1 receptor agonists, is considered after a structured lifestyle intervention at a BMI of around 27 or above — or from a BMI of 25 if you have a related condition such as type 2 diabetes, prediabetes, high blood pressure, abnormal cholesterol, fatty liver, or sleep apnoea.

Check your BMI using Indian cut-offs, or complete the eligibility form.

To check your eligibility for the Karespot programme please fill the eligibility check form in the link.

Our prescribing clinicians are registered medical doctors in India listed with the relevant medical council. Each prescriber holds at least an M.B.B.S. degree along with an M.D (Internal Medicine) and maintains professional standards through ongoing learning and clinical best practices.

Karespot clinicians take a holistic, patient-centred approach — focusing on long-term outcomes, clear communication, and a supportive doctor–patient relationship throughout the programme.

Clinical research suggests that GLP-1/GIP medicines are among the most effective prescription options currently available for weight loss. A large study of more than 2,500 participants (published in the NEJM as part of the SURMOUNT-1 trial) reported average weight loss of up to 20.9% after 72 weeks with tirzepatide 15mg therapy, compared with up to 14.9% with GLP-1–only treatment.

At Karespot, eligible patients may be prescribed either a GLP-1 medicine or a dual GLP-1/GIP medicine. The most suitable option depends on your health profile, past medical history, treatment preferences, and weight goals. This decision is made together with your Karespot doctor during the initial medical consultation.

Read more: Wegovy vs Ozempic — what is the difference?

The most common side effects are gastrointestinal — nausea, vomiting, constipation, diarrhoea, and reflux. They are usually worst in the first weeks and after each dose increase, and they typically settle with time.

This is exactly why the dose starts low and is raised slowly, and why medical supervision matters. Rarer but more serious risks, including pancreatitis and gallbladder problems, should be discussed with your doctor alongside your personal and family medical history.

Read more: side effects of Mounjaro and how to manage them.

Karespot's dose-escalation plan is designed to help your body adjust gradually, reducing the chance of side effects while supporting steady results. A typical semaglutide schedule runs: Weeks 1–4: 0.25 mg · Weeks 5–8: 0.5 mg · Weeks 9–20: 1.0 mg, increasing further as tolerated. Tirzepatide (Mounjaro) follows a different schedule, starting at 2.5 mg.

Your doctor may adjust either plan based on your tolerance and goals. Our Care Team stays in touch at every step to help you manage side effects and connect you with your prescriber when needed.

Read more: Mounjaro doses — what to expect at each stage.

Often, yes — unless the underlying habits and metabolic drivers have been addressed. We would rather tell you this honestly upfront.

Obesity is a chronic, relapsing condition. GLP-1 medicines work while you take them; when they stop, appetite signals return, and studies show a significant proportion of lost weight is regained over the following year.

This is precisely why Karespot pairs medication with dietician coaching, psychologist support, and strength-based activity — so that when the medication ends, the habits and the muscle remain. Medication alone is a weak long-term strategy.

Yes — we deliver to almost all of India through our licensed pharmacy partner, in plain, unmarked packaging with no identifying labels on the outside.

A small number of regions are not currently served, including most of the North East, the Andaman & Nicobar Islands, and Lakshadweep. You can check your own state using the delivery checker on this page.

We understand how frustrating this can be, and we want to make sure your treatment is never interrupted. Since all products on Karespot are procured through verified, registered distributors of these medications, any defective device, including a broken or jammed pen, is eligible for a replacement. Please reach out to our support team right away and we will arrange a replacement for you promptly.